Do you want to read an article? Please log in or register.
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study
Lung, Respiratory and Thoracic Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM
doi: 10.1016/j.lungcan.2020.03.024.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
★ 3
Recommended by
Alexander Meisel, Faculty Member
Lung Cancer.
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J
doi: 10.1016/j.lungcan.2020.10.003.Visit the original publication at ncbi.nlm.nih.gov
Lung, Respiratory and Thoracic CancerRadio-Oncology
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Lancet.
Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, Morgan S, Lee C, Waite K, Bayman N, Pugh C, Sydes B, Stephens R, Parmar MK, Langley RE
doi: 10.1016/
Lung, Respiratory and Thoracic Cancer
A phase II study of osimertinib for radiotherapy-naïve CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L)
J Thorac Oncol
Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Mukae H, Ito K, Chibana K, Inoue K, Miura S, Tanaka K, Ebi N, Suetsugu T, Harada T, Kirita K, Yokoyama T, Nakatani Y, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K
doi: 10.1016/j.jtho.2021.07.026
Lung, Respiratory and Thoracic Cancer
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
J Clin Oncol.
Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA
doi: 10.1200/JCO.2017.74.7576.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
J Clin Oncol.
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR, KEYNOTE-604 Investigators
doi: 10.1200/JCO.20.00793.
Lung, Respiratory and Thoracic Cancer
Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study
PLoS One
Fuchs J, Früh M, Papachristofilou A, Bubendorf L, Häuptle P, Jost L, Zippelius A, Rothschild SI
doi: 10.1371/journal.pone.0253601
Lung, Respiratory and Thoracic Cancer
Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort
J Cancer.
Conen K, Hagmann R, Hess V, Zippelius A, Rothschild SI
doi: 10.7150/jca.16211